BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

10416 related articles for article (PubMed ID: 16767915)

  • 21. Isolated limb infusion for malignant melanoma: predictors of response and outcome.
    Barbour AP; Thomas J; Suffolk J; Beller E; Smithers BM
    Ann Surg Oncol; 2009 Dec; 16(12):3463-72. PubMed ID: 19830498
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Isolated hyperthermic perfusion of extremities in malignant melanoma with melphalan and tumor necrosis factor].
    Kettelhack C; Hohenberger P; Schlag PM
    Langenbecks Arch Chir Suppl Kongressbd; 1996; 113():127-9. PubMed ID: 9101810
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcomes following isolated limb infusion for melanoma. A 14-year experience.
    Kroon HM; Moncrieff M; Kam PC; Thompson JF
    Ann Surg Oncol; 2008 Nov; 15(11):3003-13. PubMed ID: 18509706
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Isolated hyperthermic limb perfusion with melphalan and tumor necrosis factor in malignant melanoma].
    Kettelhack C; Hohenberger P; Schlag PM
    Dtsch Med Wochenschr; 1997 Feb; 122(7):177-81. PubMed ID: 9072487
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hyperthermic isolated perfusion with tumor necrosis factor-alpha and doxorubicin for the treatment of limb-threatening soft tissue sarcoma: the experience of the Italian Society of Integrated Locoregional Treatment in Oncology (SITILO).
    Di Filippo F; Giacomini P; Rossi CR; Santinami M; Garinei R; Anzà M; Deraco M; Botti C; Perri P; Cavaliere F; Di Angelo P; Sofra C; Sperduti I; Pasqualoni R; Di Filippo S; Corrias F; Armenti A; Ferraresi V
    In Vivo; 2009; 23(2):363-7. PubMed ID: 19414428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Isolated limb perfusions with tumor necrosis factor and melphalan for locally recurrent soft tissue sarcoma in previously irradiated limbs.
    Lans TE; Grünhagen DJ; de Wilt JH; van Geel AN; Eggermont AM
    Ann Surg Oncol; 2005 May; 12(5):406-11. PubMed ID: 15915375
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Isolated limb perfusion with tumor necrosis factor and melphalan for non-resectable soft tissue sarcomas: long-term results on efficacy and limb salvage in a selected group of patients.
    Cherix S; Speiser M; Matter M; Raffoul W; Liénard D; Theumann N; Mouhsine E; Mirimanoff RO; Leyvraz S; Lejeune FJ; Leyvraz PF
    J Surg Oncol; 2008 Sep; 98(3):148-55. PubMed ID: 18668638
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Complete response of melanoma-in-transit metastasis after isolated limb perfusion with tumor necrosis factor alpha and melphalan without massive tumor necrosis: a clinical and histopathological study of the delayed-type reaction pattern.
    Nooijen PT; Eggermont AM; Schalkwijk L; Henzen-Logmans S; de Waal RM; Ruiter DJ
    Cancer Res; 1998 Nov; 58(21):4880-7. PubMed ID: 9809994
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TNF-based isolated limb perfusion in unresectable extremity desmoid tumours.
    Grünhagen DJ; de Wilt JH; Verhoef C; van Geel AN; Eggermont AM
    Eur J Surg Oncol; 2005 Oct; 31(8):912-6. PubMed ID: 16098709
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term follow-up of 163 consecutive patients treated with isolated limb perfusion for in-transit metastases of malignant melanoma.
    Olofsson R; Mattsson J; Lindnér P
    Int J Hyperthermia; 2013 Sep; 29(6):551-7. PubMed ID: 23865737
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US.
    Beasley GM; Caudle A; Petersen RP; McMahon NS; Padussis J; Mosca PJ; Zager JS; Hochwald SN; Grobmyer SR; Delman KA; Andtbacka RH; Noyes RD; Kane JM; Seigler H; Pruitt SK; Ross MI; Tyler DS
    J Am Coll Surg; 2009 May; 208(5):706-15; discussion 715-7. PubMed ID: 19476821
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Results of isolated lower limb perfusion for loco-regional advanced/recurrent melanoma using borderline true hyperthermia plus additional bolus of melphalan. A critical analysis of homogeneous cases.
    Pace M; Gattai R; Mascitelli EM; Millanta L
    J Surg Oncol; 2011 Dec; 104(7):718-23. PubMed ID: 21721008
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Isolated limb infusion as palliative treatment for advanced limb disease in patients with AJCC stage IV melanoma.
    Kroon HM; Lin DY; Kam PC; Thompson JF
    Ann Surg Oncol; 2009 May; 16(5):1193-201. PubMed ID: 19224288
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma.
    Grunhagen DJ; de Wilt JH; Graveland WJ; Verhoef C; van Geel AN; Eggermont AM
    Cancer; 2006 Apr; 106(8):1776-84. PubMed ID: 16541435
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hyperthermic isolated limb perfusion with tumor necrosis factor alone for melanoma.
    Posner MC; Lienard D; Lejeune FJ; Rosenfelder D; Kirkwood J
    Cancer J Sci Am; 1995; 1(4):274-80. PubMed ID: 9166488
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Isolated limb perfusion for melanoma patients--a review of its indications and the role of tumour necrosis factor-alpha.
    Grünhagen DJ; de Wilt JH; van Geel AN; Eggermont AM
    Eur J Surg Oncol; 2006 May; 32(4):371-80. PubMed ID: 16520016
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Palliation of regional symptoms of advanced extremity melanoma by isolated limb perfusion with melphalan and high-dose tumor necrosis factor.
    Fraker DL; Alexander HR; Andrich M; Rosenberg SA
    Cancer J Sci Am; 1995; 1(2):122-30. PubMed ID: 9166465
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term results of melphalan-based isolated limb perfusion with or without low-dose TNF for in-transit melanoma metastases.
    Rossi CR; Pasquali S; Mocellin S; Vecchiato A; Campana LG; Pilati P; Zanon A; Nitti D
    Ann Surg Oncol; 2010 Nov; 17(11):3000-7. PubMed ID: 20429035
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Isolated limb perfusion with the tumor-targeting human monoclonal antibody-cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma.
    Papadia F; Basso V; Patuzzo R; Maurichi A; Di Florio A; Zardi L; Ventura E; González-Iglesias R; Lovato V; Giovannoni L; Tasciotti A; Neri D; Santinami M; Menssen HD; De Cian F
    J Surg Oncol; 2013 Feb; 107(2):173-9. PubMed ID: 22674435
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hyperthermic isolated limb perfusion (HILP) in malignant melanoma. Experience with 101 patients.
    Knorr C; Meyer T; Janssen T; Goehl J; Hohenberger W
    Eur J Surg Oncol; 2006 Mar; 32(2):224-7. PubMed ID: 16289716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 521.